Document is current
Any future updates will be listed below
-
Authors
Alnaqbi, Khalid A. https://orcid.org/0000-0001-5875-4663
Alaswad, Mohammed https://orcid.org/0009-0001-8592-0898
Al Araimi, Tariq https://orcid.org/0009-0009-6200-799X
Mahmoud, Amr A. A. https://orcid.org/0000-0003-2959-0692
Al Emadi, Samar https://orcid.org/0000-0001-7942-4831
Al Rayes, Hanan https://orcid.org/0000-0002-6322-0831
Mohammed, Khuloud
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
- License Information
-
More Information
Article History
Received: 25 June 2025
Accepted: 21 July 2025
First Online: 7 August 2025
Declarations
:
: XB reports receiving honoraria, research and development grants, and/or consulting fees from AbbVie, Advanz, Alexion, Alfasigma, Amgen, BMS, Cesas, Celltrion, Clarivate, Galapagos, GreyWolf, Janssen (J&J), Lilly, MoonLake, Novartis, PeerVoice, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB, and Zuellig. The remaining authors declare no relevant financial or non-financial interests to disclose.
: In the United Arab Emirates, ethical approval was obtained from the Abu Dhabi Health Research and Technology Ethics Committee (ADHRTC) (Protocol No. DOH/CVDC/2021/511) on 7 April 2021. In Oman, ethical approval was granted by the Ministry of Health, Directorate General of Planning and Studies (Protocol No. MoH/CSR/21/24652) on 21 April 2021.
: External editing services were not used in preparing this manuscript. ChatGPT (OpenAI, version GPT-4) was used only for copy editing purposes such as grammar and clarity, and not for content generation or interpretation.
: Informed consent from participants was taken at the beginning of the survey.
